Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05564403 · ClinicalTrials.gov registry record · Phase 2

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

A Phase 2 study of Stage III Intrahepatic Cholangiocarcinoma AJCC v8 and Advanced Biliary Tract Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
66
Enrollment target
20
Study locations

NCT05564403 is a Phase 2 study of Stage III Intrahepatic Cholangiocarcinoma AJCC v8 and Advanced Biliary Tract Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 66 participants, above the 35-participant average among 8 other Stage III Intrahepatic Cholangiocarcinoma AJCC v8 trials with a reported enrollment target (89% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05564403, a Phase 2 study of Stage III Intrahepatic Cholangiocarcinoma AJCC v8 and Advanced Biliary Tract Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
66 participants
Enrollment target
20
Study locations

Study Summary

This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting). Fluorouracil is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It works by killing tumor cells. Leucovorin may help the other drugs in the mFOLFOX6 chemotherapy regimen work better by making tumor cells more sensitive to the drugs. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps to stop or slow the spread of tumor cells. Giving binimetinib in combination with mFOLFOX6 chemotherapy may be effective in shrinking or stabilizing advanced biliary tract cancers in the 2nd line setting.

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy Procedure
  • PROCEDURE Bone Scan
  • DRUG Binimetinib

Study Locations (20)

Florida

  • UM Sylvester Comprehensive Cancer Center at Aventura - Aventura
  • UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
  • UF Health Cancer Institute - Gainesville - Gainesville
  • Mayo Clinic in Florida - Jacksonville
  • University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
  • UM Sylvester Comprehensive Cancer Center at Kendall - Miami
  • UM Sylvester Comprehensive Cancer Center at Plantation - Plantation

Hawaii

  • Hawaii Cancer Care Inc - Waterfront Plaza - Honolulu
  • Queen's Cancer Cenrer - POB I - Honolulu
  • Queen's Medical Center - Honolulu
  • Queen's Cancer Center - Kuakini - Honolulu
  • Hawaii Cancer Care - Westridge - ‘Aiea

California

  • UC San Diego Moores Cancer Center - La Jolla
  • Cedars Sinai Medical Center - Los Angeles
  • Presbyterian Intercommunity Hospital - Whittier

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham
  • University of South Alabama Mitchell Cancer Institute - Mobile

Arizona

  • Mayo Clinic Hospital in Arizona - Phoenix

Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2024-02-09
Est. Completion 2026-05-01
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT05564403

The ClinicalTrials.gov registry entry for NCT05564403 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 8 other Stage III Intrahepatic Cholangiocarcinoma AJCC v8 trials with a reported enrollment target (89% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Stage III Intrahepatic Cholangiocarcinoma AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05564403 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Hawaii, California.

Frequently Asked Questions

What is clinical trial NCT05564403 about?

NCT05564403 is a clinical study titled "Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)". This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (adv...

What is the current status of trial NCT05564403?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-02-09. Estimated completion is 2026-05-01.

What conditions does trial NCT05564403 study?

This clinical trial studies the following conditions: Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Advanced Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v8.

What interventions are being tested in trial NCT05564403?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Bone Scan (PROCEDURE), Binimetinib (DRUG).

Who is sponsoring clinical trial NCT05564403?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05564403 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage III Intrahepatic Cholangiocarcinoma AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.